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Aim: Hepatitis A can be prevented by vaccination. The aim of this study was to determine seropositivity for hepatitis A before vaccination
in healthy children 12 and 24 months of age and compare seroconversion rates after vaccination between these 2 groups.
Materials and methods: Forty-nine children aged 1 year (Group 1) and 51 children aged 2 years (Group 2) were included in the study.
Inactive hepatitis A vaccine (Avaxim, 80 antigenic subtypes, 0.5 mL) were administered to every child in 2 doses, 6 months apart.
Anti-hepatitis A virus (HAV) IgG and IgM antibodies were detected by Architect HAVAb-IgG and HAVAb-IgM (Abbott, Wiesbaden,
Germany) test kits.
Results: Nine percent of the children were seropositive for anti-HAV IgG before vaccination. The seroconversion rate at 2 weeks was
34% and 44% in Group 1 and Group 2, respectively. At 4 weeks the seroconversion rate was 87.7% and 90.1% in Group 1 and Group
2, respectively. All of the children who completed the vaccination program were seropositive at 28 weeks (after the second dose). No
serious adverse reaction was observed in any of the children.
Conclusion: It was determined that Avaxim, including 80 antigen units, is safe and immunogenic in healthy children 12 and 24 months
of age.
Key words: Hepatitis A vaccine, seroprevalence, safety, immunogenicity, children

1. Introduction
Hepatitis A is an acute, usually self-limiting infection
of the liver caused by the hepatitis A virus (HAV). HAV
is transmitted from person to person, primarily by the
fecal–oral route. The severity of illness varies with age,
being more symptomatic in older children and adults.
The prevalence of HAV infection is associated with the
socioeconomic status of the country and the region (1,2).
HAV has one serotype, so immunity by IgG remains
for life after infection. Detection of the anti-HAV IgG
antibody can be used in seroprevalence investigations (1).
In Turkey, the seroprevalence of antibodies to HAV in
the general population shows geographic and age-related
differences most likely associated with socioeconomic and
cultural conditions. A recent study showed that the rate
of seropositivity for anti-HAV IgG was over 80% in the
age group of 5–9 years old and more than 90% after 14
years of age in the southeastern and eastern regions. The
seropositivity rate was lower than 50% in the age group
of 5–9 years old and under 80% after 14 years of age in
the central and western regions of Turkey (2). In a study
* Correspondence: solmaz@uludag.edu.tr

by Alabaz et al. (3), maternal hepatitis A antibodies in
infants born to hepatitis A antibody-positive mothers were
detected in 93.9%, 36.1%, 13.6%, and 6.1% at birth and at
12, 18, and 21 months of age, respectively. Additionally,
two-thirds of infants over the age of 12 months were at
high risk of acquiring hepatitis A infection. Several studies
indicated that passively acquired anti-HAV antibodies
interfere with the immune response to hepatitis A vaccine
(4,5). Letson et al. (6) reported that infants born to mothers
who were anti-HAV–positive had a poorer response to the
vaccine series. In a recent study by Shapapov et al. (7), 197
infants and young children were randomized by maternal
anti-HAV status into 3 groups to receive a 2-dose hepatitis
A vaccine: group 1 at 6 and 12 months, group 2 at 12
and 18 months, and group 3 at 15 and 21 months of age.
Anti-HAV levels were measured at 1 and 6 months and
at 3, 5, 7, and 10 years after the second dose of hepatitis
A vaccination. The results from this study suggest that
the seropositivity induced by hepatitis A vaccine given
to children of <2 years of age persists for at least 10 years
regardless of the presence of maternal anti-HAV (7). After
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the introduction of hepatitis A vaccine in 1995, it became
a vaccine-preventable disease. The American Academy
of Pediatrics recommends hepatitis A vaccination after
1 year of age (8). The highest incidence rates of HAV
infection have previously been reported to occur in
developing countries; these data suggest that hepatitis A
vaccine should be included in these countries’ national
immunization schedule (9,10). Hepatitis A vaccine was
included in the Turkish National Immunization Program
for use in children aged 18 months or older in September
2012.
The aim of this study was to determine seropositivity
for hepatitis A before vaccination in healthy children 12
and 24 months of age and to compare seroconversion rates
after vaccination between these 2 groups.
2. Materials and methods
This was a prospective study conducted at the Uludağ
University Hospital in Bursa, Turkey. The study included
healthy children who were admitted for a routine
vaccination program at the Well Baby Clinic. This study
was conducted in the western regions of Turkey, which
have intermediate endemicity. The children were grouped
as 1 year old (Group 1: G1) and 2 years old (Group 2: G2).
The Uludağ University Medical School Ethics Committee
approved the study, which was conducted in accordance
with the Declaration of Helsinki and its amendments,
and Good Clinical Practice guidelines were followed
throughout. Written informed consent was obtained
from the parents of each child prior to study enrollment.
Children were excluded if they had an acute febrile
illness, a chronic immunocompromising disease (e.g.,
leukemia, cancer, AIDS), immunosuppressive treatment
(e.g., chemotherapy, systemic corticosteroid for at least 2
weeks), a previous hepatitis A vaccination, or a history of
hepatitis A.
Avaxim (80 U) was obtained from Sanofi Pasteur
(Lyon, France), which supported this study. Avaxim 80
U Pediatric was prepared from the HAV strain GBM,
inactivated with formaldehyde, and contained 80 antigen
units of hepatitis A antigen protein per 0.5 mL dose,
adsorbed onto 0.15 mg of aluminum hydroxide. Vaccines
were stored between 2 °C and 8 °C throughout the study.
Avaxim was administered by intramuscular injection
into the deltoid region using a 16-mm 25-gauge needle
in 2 doses, 6 months apart. The children were followed
for 30 min after vaccination for early adverse reactions.
The patients were informed about late adverse reactions
and were called by telephone on the 1st, 3rd, and 5th
days after vaccination. Local adverse reactions were
pain, redness, edema, and hematoma; systemic adverse
reactions included fever (axillary temperature of >37.5
°C), headache, and abdominal discomfort.
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After physical examination, blood samples for antiHAV antibodies were obtained by venipuncture before the
first dose of vaccine (S0; serum 0), 2 weeks after the first
injection (S1; serum 1), at 24 weeks (S2; serum 2) before
the second dose, and at 28 weeks after the second dose
of vaccination (S3; serum 3). After serum samples were
centrifuged at 5000 rpm for 3 min, sera were stored at –70
°C until tested.
Anti-HAV IgG and IgM antibody levels were measured
at the Microbiology Laboratory of the university by the
Architect system of Abbott study kits (11). Anti-HAV IgG
values were measured for each serum sample (4 serum
samples for every child) and anti-HAV IgM values were
measured only from samples taken before vaccination
and at 4 weeks after the first dose. An anti-HAV IgG S/
CO [serum sample result/cut-off relative light unit (RLU)]
of <1 was considered negative, and >1 was considered
positive. The cut-off RLU was calculated by multiplying
the medium calibrator RLU value by 0.29. The sensitivity
of the test for measuring antibodies was >98% and the
specificity was >99.17% (12). S/CO ratios were compared
before the first dose of the vaccination, at 2 weeks and at 4
weeks after the first dose, and at 28 weeks after the second
dose.
Statistical analysis was performed using SPSS (SPSS,
Inc., Chicago, IL, USA). Descriptive statistics [means and
standard deviations (SDs) for continuous variables and
counts and percentages for categorical variables] were
used to describe the results. The results of the data were
statistically assessed by the Shapiro–Wilk test, chi-square
test, Mann–Whitney U test, and Wilcoxon tests. A P-value
of less than 0.05 was considered significant.
3. Results
A total of 100 children, of whom 49 were in G1 and 51
were in G2, were enrolled in the study. In G1 45 children
and in G2 49 children completed the study. The S1 samples
of 2 children in G1 and the S1 sample of 1 child in G2 were
hemolyzed and could not be tested. The G1 group was
composed of 19 females (38.7%) and 30 males (61.3%).
The G2 group was composed of 19 females (37.2%) and
32 males (62.8%). There was no significant difference
between the 2 groups in terms of sex.
The seropositivity of anti-HAV IgG before vaccination
was 10.2% for G1 and 7.8% for G2 (Table 1). The
seropositivity of anti-HAV IgG before vaccination was not
statistically significant between the 2 groups (P = 0.74).
The seroconversion rates are given in Table 1. There
were no significant differences between the 2 groups in
terms of seroconversion rates. The seroconversion rates for
S1, S2, and S3 were 39%, 89%, and 100% (respectively) for
all children in the study.
None of the children in G1 and G2 before vaccination
had clinical signs of active hepatitis A infection. In
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Table 1. Efficiency of vaccination according to serology of anti-HAV before vaccination in G1 and G2.
Anti-HAV IgG (+) positivity
S0
n/N (%)

S1
n/N (%)

S2
n/N (%)

S3
n/N (%)

G1
Seronegative children before vaccination (n = 44)
Seropositive children before vaccination (n = 5)a
Total (n = 49)

44/49 (89.8)
5/49 (10.2)
49/49 (100)

12/43 (27.9)
4/4 (100)
16/47 (34)

38/44 (86.3)
5/5 (100)
43/49 (87.7)

41/41 (100)
4/4 (100)
45/45 (100)

G2
Seronegative children before vaccination (n = 47)
Seropositive children before vaccination (n = 4)
Total (n = 51)

47/51 (92.2)
4/51 (7.8)
51/51 (100)

19/47 (40.4)
3/3 (100)
22/50 (44)

42/47 (89.3)
4/4 (100)
46/51 (90.1)

46/46 (100)
3/3 (100)
49/49 (100)

P
Seronegative children before vaccination (n = 91)
Seropositive before vaccination (n = 9)
Total (n = 100)

P = 0.70
P = 0.74
P=*

P = 0.37
P=*
P = 0.55

P = 0.69
P=*
P = 0.70

P=*
P=*
P=*

a: Serum of one subject in S1 and in S2 could not be tested because it was hemolyzed.
*Not applicable.
S0: Serum samples before first dose of vaccination; S1: serum samples 15 days after first dose of vaccination; S2: serum samples 30 days
after first dose and before second dose of vaccination; S3: serum samples 30 days after second dose of vaccination.

addition, alanine aminotransferase (ALT), aspartate
aminotransferase (AST), and bilirubin levels were not
high, and anti-HAV IgM tests were negative. Only 6
children (6%) had borderline positive anti-HAV IgM levels
in S2 (the limit of positivity S/CO was 0.7–1.0).
The S/CO ± SD ratios of S0, S1, S2, and S3 in G1 and
G2 are shown in Tables 2 and 3. There were statistically
significant differences between seronegative children
in G1 and seropositive ones in G1 with respect to the S/
CO ratio in S1; however, no significant differences were
seen between S2 and S3 in these groups. The S/CO ratios
were not statistically significant between S2 and S3 in
seronegative children in G2 and seropositive ones in G2.
A significant difference was seen in S1 in seronegative and
seropositive children in G2.
The mean S/CO ± SD ratios and seroconversion rates in
G1 and G2 are shown in Table 4. No significant difference
was found among S1, S2, and S3 in G1 and G2. The mean
S/CO ± SD ratios in S0, S1, S2, and S3 are shown in Table
5. There were statistically significant differences between
S0 and S1 in seronegative and seropositive children. No
difference was found between S2 and S3 in these 2 groups.
The S/CO ratios of S1, S2, and S3 in G1 (n = 49) and G2
(n = 51) increased 2.7, 8.5, and 29 times and 2.9, 11.2, and
35 times, respectively. There was no significant difference
between the percentage changes of S/CO ratio in S1, S2,
and S3 in G1 and G2 compared with the prevaccination
values. The S/CO ratios of S1, S2, and S3 in seronegative (n
= 91) and seropositive (n = 9) children increased 4.2, 16.4,
and 55.2 times and 1.5, 2.3, and 5.3 times, respectively. No

difference was seen between the percentage changes of S/
CO ratio in S1 of seronegative and seropositive children
compared with the prevaccination values. The increase in
the percentage changes of the S/CO ratio was significant
between S2 and S3 in seronegative and seropositive
children (16.4 vs. 2.3 times, P < 0.001; 55.2 vs. 5.3 times, P
< 0.001) compared with the prevaccination values.
The local and systemic adverse reactions of hepatitis A
vaccination are shown in Table 6. No immediate systemic
adverse reaction occurring within 30 min of vaccination
was noted in any of the children. Local adverse reactions
consisted of mild pain and redness at the injection site
that resolved spontaneously. The rate of systemic adverse
reactions after the administration of the first dose of
vaccine, such as myalgia, arthralgia, gastrointestinal
symptoms, and headache, was 6.1%, 7.8%, and 7% in
G1, G2, and all children in the study group (n = 100),
respectively. After the second dose of vaccine, the rate
of systemic adverse reactions was 6.1% in G2 while no
reaction occurred in G1. After the first dose of vaccination,
no significant differences were found between G1 and G2
with regard to the rates of the local and systemic adverse
reactions and local and/or systemic adverse reactions
(P = 0.71, P = 099, and P = 0.63, respectively). After the
second dose of vaccination, no significant differences were
found between G1 and G2 with regard to the rates of local
and systemic adverse reactions (P = 0.11 and P = 0.24,
respectively); however, a significant difference was found
with regard to the rates of local and/or systemic reactions
(P = 0.013).
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Table 2. S/CO levels and seroconversion rates according to anti-HAV IgM serology in G1 and G2.
Anti HAV IgG S/CO ± SD values
S/CO ≥ 1/N (%)

S2 Anti-HAV IgM serology
n/N (%)

G1, n = 49

G2, n = 51

Total,
n = 100

S0

S1

S2

S3

Anti-HAV IgM (+)
2/49 (4.1)

0.47 ± 0.07
0/2 (0)

Anti-HAV IgM (-)
47/49 (95.9)

0.50 ± 0.67e
5/47 (10.6)

1.43 ± 1.85f
16/45 (35.5)

4.37 ± 3.31g
41/47 (87.2)

14.58 ± 2.21h
43/43 (100)

Anti-HAV IgM (+)
4/51 (7.8)

0.18 ± 0.05a
0/4 (0)

0.70 ± 0.53b
2/4 (50)

2.65 ± 1.50c
4/4 (100)

14.46 ± 0.69d
4/4 (100)

Anti-HAV IgM (-)
47/51 (92.2)

0.40 ± 0.79e
4/47 (8.5)

1.22 ± 1.51f
20/46 (43.4)

4.66 ± 3.47g
42/47 (89.3)

14.13 ± 2.98h
45/45 (100)

Anti-HAV IgM (+)
6/100 (6)

0.28 ± 0.16i
0/6 (0)

0.62 ± 0.43j
2/6 (33.3)

2.51 ± 1.38k
6/6 (100)

14.02 ± 2.07l
6/6 (100)

Anti-HAV IgM (-)
94/100 (94)

0.46 ± 0.75i
9/94 (9.5)

1.33 ± 1.68j
36/91 (39.5)

4.52 ± 3.37k
83/94 (88.2)

14.35 ± 2.63l
88/88 (100)

0.47 ± 0.02
0/2 (0)

a

b

2.21 ± 1.60
2/2 (100)

c

13.14 ± 4.21d
2/2 (100)

S0: Serum samples before first dose of vaccination; S1: serum samples 15 days after first dose of vaccination; S2: serum samples 30 days
after first dose and before second dose of vaccination; S3: serum samples 30 days after second dose of vaccination.
For a, P = 0.66; b, P = 0.99; c, P = 0.66; d, P = 0.33; e, P = 0.53; f, P = 0.54; g, P = 0.71; h, P = 0.39; i, P = 0.98; j, P = 0.84; k, P = 0.39; l, P
= 0.22.
Table 3. Mean values and positivity rates of S/CO* according to vaccination in G1.
G1

Seronegative children before
vaccination (n = 44)
Seropositive children before
vaccination (n = 5)
Total children in G1 (n = 49)

S0
(N = 49)

S1
(N = 47)

S2
(N = 49)

S3
(N = 41)

S/CO ± SD

0.33 ± 0.21

1.23 ± 1.73a

4.07 ± 3.10b

14.50 ± 2.20c

S/CO ≥ 1/N
(%)

0/44
(0)

12/43
(27.9)

38/44
(86.3)

41/41
(100)

S/CO ± SD

2.04 ± 1.19

3.07 ± 2.26a

6.19 ± 4.54b

14.64 ± 3.25c

S/CO ≥ 1/N
(%)

5/5
(100)

4/4
(100)

5/5
(100)

4/4
(100)

S/CO ± SD

0.50 ± 0.65

1.38 ± 1.83

4.29 ± 3.28

14.51 ± 2.27

S/CO ≥ 1/N
(%)

5/49
(10.2)

16/47
(34)

43/49
(87.7)

45/45
(100)

For a, P = 0.011; for b, P = 0.26; for c, P = 0.47.
S0: Serum samples before first dose of vaccination; S1: serum samples 15 days after first dose of vaccination; S2: serum samples 30 days
after first dose and before second dose of vaccination; S3: serum samples 30 days after second dose of vaccination.
*The values above are only S/CO results (serum sample / cutoff RLU) and are not the geometric mean titers of serum antibody
concentrations.

4. Discussion
HAV is a common type of infectious hepatitis. The
prevalence of anti-HAV antibody varies among different
ages, countries, and even different regions of the same
country. The decrease in the seroprevalence of antiHAV antibody is usually explained by the improvement
in socioeconomic conditions, access to safe drinking
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water, improvement of sanitation facilities, and effective
vaccination program (12,13). The prevalence of hepatitis
A in developed countries varies among age groups, being
lower than 20% in subjects of <50 years of age (14). In a
study performed in Canada, the prevalence was found
to be <20% among children and 40%–60% in adults of
>40 years old (15,16). Seroprevalence rates vary among
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Table 4. Mean values and positivity rates of S/CO according to vaccination in G2.
G2

Seronegative children before
vaccination (n = 47)
Seropositive children before
vaccination (n = 4)
Total children in G2 (n = 51)

S0
(N = 51)

S1
(N = 50)

S2
(N = 51)

S3
(N = 49)

S/CO ± SD

0.20 ± 0.07

1.01 ± 1.27a

4.48 ± 3.44b

14.23 ± 2.93c

S/CO ≥ 1/N
(%)

0/47
(0)

19/47
(40.2)

42/47
(89.3)

46/46
(100)

S/CO ± SD

2.79 ± 1.51

3.94 ± 1.74a

4.81 ± 3.06b

12.99 ± 1.40c

S/CO ≥ 1/N
(%)

4/4
(100)

3/3
(100)

4/4
(100)

3/3
(100)

S/CO ± SD

0.40 ± 0.79

1.18 ± 1.46

4.51 ± 3.39

14.15 ± 2.86

S/CO ≥ 1/N
(%)

4/51
(7.8)

22/50
(44)

46/51
(90.1)

49/49
(100)

For a, P = 0.002; for b, P = 0.74; for c, P = 0.18.
S0: Serum samples before first dose of vaccination; S1: serum samples 15 days after first dose of vaccination; S2: serum samples 30 days
after first dose and before second dose of vaccination; S3: serum samples 30 days after second dose of vaccination.

European countries, being medium in the eastern and
southern regions of Europe, but low in the western and
northern regions (13).
The prevalence of hepatitis A is high in Turkey, but it
is heterogenic among different regions of the country. In a
study conducted in different regions of Turkey, the mean
prevalence of HAV infection was 71.3% for all ages, and it
was higher in the eastern regions than the western regions
of Turkey (2,17). In one study, 14% of subjects between 1
and 4 years of age and 36% between 5 and 9 years of age
were found to be HAV-positive in the western provinces
(17). In another study in the southern regions of the
country, seropositivity was found to be 78.1% and 86.9%
in the same age groups, respectively (18). A recent study
from Turkey reported that hepatitis A seroprevalence was
23.5% in children at 12 months of age (19). In our study,

the seropositivity rate of hepatitis A was 10.2% and 7.8%
in children 12 and 24 months of age, respectively. The rate
of seropositivity in our study was lower than the rates in
some published reports (3,19). Unfortunately, we were
unable to determine whether these antibodies in children
12 months of age were of maternal origin or the result of
a previous infection. The decrease in the seropositivity of
antibodies by 24 months of age and the significant increase
in seroconversion rates after vaccination demonstrated
that the seropositivity was due to maternal antibodies
much more so than to acquired infections.
In a study performed in the United States among infants
born to seropositive mothers, seropositivity rates at 6, 12,
and 15 months of age were 94%, 15%, and 3%, respectively
(20). In a study from Turkey, maternal antibodies were
found to be positive in 85% of newborns. In the same

Table 5. S/CO rates of children in the study (1 and 2 years old).
Total

S/CO of ≥1 / <1
(%)

0
(N = 100)

S1
(N = 97)

S2
(N = 100)

S3
(N = 94)

9/91
(9)

38/59
(39.1)

89/11
(89)

94/0
(100)

S/CO ± SS in seronegative children
before vaccination

0.26 ± 0.17

S/CO ± SS in seropositive children
before vaccination

2.37 ± 1.31

S/CO ± SS in all of the children

1.11 ± 1.50
P = 0.001

0.45 ± 0.73

4.28 ± 3.27
P = 0.001

3.44 ± 1.94
1.28 ± 1.64

P = 0.33
5.58 ± 3.79
4.40 ± 3.32

14.36 ±
2.60
13.93 ±
2.59

P = 0.67

14.33 ± 2.59

S0: Serum samples before first dose of vaccination; S1: serum samples 15 days after first dose of vaccination; S2: serum samples 30 days
after first dose and before second dose of vaccination; S3: serum samples 30 days after second dose of vaccination.
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Table 6. Local and systemic side effects after vaccination in G1 and G2.

G1,
N = 49
G2,
N = 51
Total,
N = 100

First dose
n/N (%)

Second dose
n/N (%)

Local n/N (%)

3/49 (6.1)a

0/45 (0)d

Systemic n/N (%)

3/49 (6.1)

0/45 (0)e

Local and/or systemic n/N (%)

6/49 (12.2)c

0/45 (0)f

Local n/N (%)

5/51 (9.8)

a

4/49 (8.1)d

Systemic n/N (%)

4/51 (7.8)b

3/49 (6.1)e

Local and/or systemic n/N (%)

9/51 (17.6)c

7/49 (14.2)f

Local n/N (%)

8/100 (8)

4/94 (4.2)

Systemic n/N (%)

7/100 (7)

3/94 (3.2)

15/100 (15)

7/94 (7.4)

Local and/or systemic n/N (%)

b

Local reaction: Pain, hyperemia, and/or induration of injection side. Systemic reaction: Myalgia, arthralgia,
abdominal discomfort, and headache.
a
: Significance of local reaction after first dose of vaccination in G1 and G2; P = 0.71. b: Significance of systemic
reactions after first dose of vaccination in G1 and G2; P = 0.99. c: Significance of local and/or systemic reactions
after first dose of vaccination in G1 and G2; P = 0.63. d: Significance of local reaction after second dose of
vaccination in G1 and G2; P = 0.11. e: Significance of systemic reactions after second dose of vaccination in G1
and G2; P = 0.24. f: Significance of local and/or systemic reactions after second dose of vaccination in G1 and
G2; P = 0.013.

study, 9% of infants at the age of 12 months and 0% at the
age of 18 months had remaining maternal antibodies, and
so infants over the age of 12 months were found to be at
high risk of acquiring HAV infection in Turkey (21).
In a study conducted in the United States to determine
the immunogenicity of an inactivated hepatitis A vaccine
in infants, 140 infants born to seronegative mothers and
108 infants born to seropositive mothers were randomized
into 3 groups, each receiving 2 doses of 720 EL.U. of
hepatitis A vaccine (HAVRIX): group 1 at ages 6 and 12
months, group 2 at ages 12 and 18 months, and group
3 at ages 15 and 21 months. In group 1, peak geometric
mean concentrations of hepatitis A antibodies between
infants born to seropositive mothers (794 mIU/mL) and
seronegative mothers (2083 mIU/mL) were significantly
different. This study suggests that the hepatitis A vaccine
is immunogenic among infants born to seronegative
and seropositive mothers if vaccination is applied at ≥12
months of age. The maternal antibody persists for at least 6
months and causes a decrease in the immune response of
the hepatitis A vaccine (8).
Similar to previous studies (3,6,20), a significant
increase in the percentage changes of the S/CO ratio after
vaccination was observed in the seronegative children
compared to the seropositive children in our study. The
percentage changes of S/CO ratios were not statistically
significant between S1, S2, and S3 in G1 and G2. As we
could not analyze the geometric mean titer of antibody
concentrations, we have no comment on the degree
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of increase in antibody titers and the duration of the
protective period.
In our study, the seroconversion rates in children at
12 and 24 months of age at 2, 4, and 28 weeks were 34%,
87.7%, and 100% and 44%, 90.1%, and 100%, respectively.
Unfortunately, we were able to measure only qualitative
levels, not the quantitative and medium antibody
concentrations. There were no significant differences
between the 2 groups in terms of seroconversion rates.
Children who completed the vaccination program were
seropositive after the second dose. In our study, the
seroconversion rates at 2 weeks were lower than in other
studies (20,22). However, our seroconversion rates at 4
and 28 weeks were quite comparable to those of previous
studies (20,22).
The positivity of anti-HAV IgM in serum samples
shortly after the vaccination can cause confusion (23). Only
<1% of subjects have anti-HAV IgM positivity 1 month
after vaccination (23). In our study, 4 weeks after the first
dose of vaccine, the rates of anti-HAV IgM positivity in the
serum samples of children at 12 and 24 months of age were
4.1% and 7.8%, respectively. In total, 6% of the children in
the study were positive for anti-HAV IgM. Although the
total 6% positivity of anti-HAV IgM levels 4 weeks after
vaccination does not demonstrate infection, it may be a
primary response to vaccination.
The safety of inactive hepatitis A vaccine was
demonstrated in several studies (22,24–26). Local adverse
reactions after vaccination have been reported to be
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between 6.1% and 17.5% and systemic adverse reactions
between 6.1% and 19.2% (22,24–26). None of the children
in our study experienced sudden allergic reaction. Local
adverse reactions occurred in 8% of children after the
first dose of vaccine and in 4.2% after the second dose.
Systemic adverse reactions occurred in 7% of children
after the first dose and in 3.2% after the second dose. Local
adverse reactions did not last longer than 3 days. Similar
to the previous studies, adverse reactions were mild in this
study (22,24).
According to the results of our study, there is no
difference between the response rates of vaccination

at 12 and 24 months of age, and also there are similar
seroconversion rates and no difference for adverse
reactions. Based on these results, hepatitis A vaccine can
be administered at 12 months of age rather than at 24
months of age. Also, according to the routine vaccination
schedule of our country, we can communicate better with
the parents of children 12 months of age, and this will
increase the vaccination rates.
In conclusion, it was demonstrated that hepatitis A
vaccine is immunogenic for 1- and 2-year-old children. We
can thus estimate that the vaccine is safe and immunogenic
for children 1 year old and older.
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